Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

N-Acetyl Cysteine and Improved Treatment Adherence

Doses used in studies

mg/day: 1,200 (median 1,200, IQR 1,200–1,200) — 1 study

Time to effect

Median: 2.8 months · IQR 2.8 months–2.8 months · Range 2.8 months–2.8 months — Reported in 1 of 1 study

Safety in these studies

Overall tolerabilityReported
Both medications were well tolerated. All adverse effects were mild.
from: Fluoxetine versus N-acetylcysteine in reducing craving in Indian men with alcohol dependen
adverse effectsReported
All adverse effects were mild.
from: Fluoxetine versus N-acetylcysteine in reducing craving in Indian men with alcohol dependen

1 of 1 paper

Fluoxetine versus N-acetylcysteine in reducing craving in Indian men with alcohol dependence syndrome: a randomised controlled trial.
- 2025-12-31
- RCT · n = 100
- East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan 35(4)
- - T Shruthi
  - L Govindan
  - S S Kanagarajan
- PubMed: 41486713
- DOI: 10.12809/eaap2591
3 Insights on
- Improved Treatment Adherence
- High evidence
- Large Human Trial
- Clinical
Treatment adherence was higher (but not significantly) in the NAC group (90.0% vs 84.0%, p = 0.38).
Effect
Neutral
Effect size
Small
Significant
No
Dose
600 mg twice/day